These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31037491)

  • 41. Chorio-retinal toxoplasmosis: treatment outcomes, lesion evolution and long-term follow-up in a single tertiary center.
    Vishnevskia-Dai V; Achiron A; Buhbut O; Berar OV; Musika AA; Elyashiv SM; Hecht I
    Int Ophthalmol; 2020 Apr; 40(4):811-821. PubMed ID: 31792847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unusual toxoplasmic chorioretinitis in advanced age: a diagnostic problem.
    Mataftsi A; Fragkou A; Vezyri E; Topouzis F; Diza E; Dimitrakos SA
    Semin Ophthalmol; 2011 Jan; 26(1):4-6. PubMed ID: 21275597
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detecting Change Using Standard Global Perimetric Indices in Glaucoma.
    Gardiner SK; Demirel S
    Am J Ophthalmol; 2017 Apr; 176():148-156. PubMed ID: 28130041
    [TBL] [Abstract][Full Text] [Related]  

  • 44. False Negative Toxoplasma Serology in an Immunocompromised Patient with PCR Positive Ocular Toxoplasmosis.
    Rajput R; Denniston AK; Murray PI
    Ocul Immunol Inflamm; 2018; 26(8):1200-1202. PubMed ID: 28700250
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Identifying glaucomatous vision loss with visual-function-specific perimetry in the diagnostic innovations in glaucoma study.
    Sample PA; Medeiros FA; Racette L; Pascual JP; Boden C; Zangwill LM; Bowd C; Weinreb RN
    Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3381-9. PubMed ID: 16877406
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Cataract Opacity Type and Glaucoma Severity on Visual Field Index.
    Chung HJ; Choi JH; Lee YC; Kim SY
    Optom Vis Sci; 2016 Jun; 93(6):575-8. PubMed ID: 27214250
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months.
    Lasave AF; Díaz-Llopis M; Muccioli C; Belfort R; Arevalo JF
    Ophthalmology; 2010 Sep; 117(9):1831-8. PubMed ID: 20471684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Swedish Interactive Threshold Algorithm for central visual field defects unrelated to nerve fiber layer.
    Hirasawa K; Shoji N
    Graefes Arch Clin Exp Ophthalmol; 2016 May; 254(5):845-54. PubMed ID: 26279004
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Classification Criteria for Toxoplasmic Retinitis.
    Standardization of Uveitis Nomenclature (SUN) Working Group
    Am J Ophthalmol; 2021 Aug; 228():134-141. PubMed ID: 33845002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis.
    Rothova A; de Boer JH; Ten Dam-van Loon NH; Postma G; de Visser L; Zuurveen SJ; Schuller M; Weersink AJ; van Loon AM; de Groot-Mijnes JD
    Ophthalmology; 2008 Feb; 115(2):306-11. PubMed ID: 17669497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of Functional Visual Acuity in Glaucoma Patients.
    Ozeki N; Yuki K; Shiba D; Tsubota K
    J Glaucoma; 2017 Mar; 26(3):223-226. PubMed ID: 27841797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ocular toxoplasmosis: advances in detection and treatment.
    Englander M; Young LH
    Int Ophthalmol Clin; 2011; 51(4):13-23. PubMed ID: 21897136
    [No Abstract]   [Full Text] [Related]  

  • 53. Comparison of visual field defects using matrix perimetry and standard achromatic perimetry.
    Patel A; Wollstein G; Ishikawa H; Schuman JS
    Ophthalmology; 2007 Mar; 114(3):480-7. PubMed ID: 17123623
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic value of specific local antibody production and nucleic acid amplification technique-nested polymerase chain reaction (nPCR) in clinically suspected ocular toxoplasmosis.
    Mahalakshmi B; Therese KL; Madhavan HN; Biswas J
    Ocul Immunol Inflamm; 2006 Apr; 14(2):105-12. PubMed ID: 16597540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toxoplasmosis.
    Bonfioli AA; Orefice F
    Semin Ophthalmol; 2005; 20(3):129-41. PubMed ID: 16282146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Performance of the visual field index in glaucoma patients with moderately advanced visual field loss.
    Lee JM; Cirineo N; Ramanathan M; Nouri-Mahdavi K; Morales E; Coleman AL; Caprioli J
    Am J Ophthalmol; 2014 Jan; 157(1):39-43. PubMed ID: 24200229
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FEATURES OF THE MACULA AND CENTRAL VISUAL FIELD AND FIXATION PATTERN IN PATIENTS WITH RETINITIS PIGMENTOSA.
    Sayman Muslubas I; Karacorlu M; Arf S; Hocaoglu M; Ersoz MG
    Retina; 2018 Feb; 38(2):424-431. PubMed ID: 28178068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sensitivity and specificity of short-duration transient visual evoked potentials (SD-tVEP) in discriminating normal from glaucomatous eyes.
    Pillai C; Ritch R; Derr P; Gonzalez A; Kopko Cox L; Siegfried J; Liebmann JM; Tello C
    Invest Ophthalmol Vis Sci; 2013 Apr; 54(4):2847-52. PubMed ID: 23513061
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Performance of an iPad Application to Detect Moderate and Advanced Visual Field Loss in Nepal.
    Johnson CA; Thapa S; George Kong YX; Robin AL
    Am J Ophthalmol; 2017 Oct; 182():147-154. PubMed ID: 28844641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toxoplasmosis.
    Dodds EM
    Curr Opin Ophthalmol; 2006 Dec; 17(6):557-61. PubMed ID: 17065925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.